Luttrull Jeffrey K, Sinclair Stephen H, Elmann Solly, Chang David B, Kent David
Ventura County Retina Vitreous Medical Group, Ventura, California, USA.
Sinclair Retina Associates, Media, Pennsylvania, USA.
Clin Ophthalmol. 2020 Oct 1;14:2983-2993. doi: 10.2147/OPTH.S268322. eCollection 2020.
To determine the effect of panmacular low-intensity/high-density subthreshold diode micropulse laser (SDM) on age-related geographic atrophy (ARGA) progression.
The retinal images of all eyes with ARGA in a previously reported database, consisting of all eyes with dry age-related macular degeneration (AMD) active in a vitreoretinal practice electronic medical record (EMR), were identified and analyzed to determine the velocity of radial linear ARGA progression during observation and after panmacular SDM.
Sixty-seven eyes of 49 patients with ARGA, mean age of 86 years were identified as having follow-up both before and after initiation of SDM treatment. All were included in the study. These eyes were followed a mean 910 days (2.5 years) prior to SDM treatment and a mean 805 days (2.2 years) after. Measurement masked to treatment vs observation found the radius of ARGA lesions progressed 1 to 540 µm per year (mean 137µm, SD 107) prior to treatment (controls); and -44 to 303 µm per year (mean 73µm, SD 59) after initiation of periodic panmacular SDM laser. Thus, the velocity of radial linear progression decreased 47% per year following panmacular SDM (p<0.0001). There were no adverse treatment effects.
In cohort of eyes with high-risk dry AMD, panmacular SDM slowed linear radial ARGA progression velocity 47% per year (p<0.0001) without adverse treatment effects. Validated, these findings would constitute an important advance in the prevention of age-related visual loss and a benchmark for future therapies.
确定全黄斑区低强度/高密度阈下二极管微脉冲激光(SDM)对年龄相关性地图样萎缩(ARGA)进展的影响。
在先前报告的数据库中识别并分析所有患有ARGA的眼睛的视网膜图像,该数据库由玻璃体视网膜科电子病历(EMR)中所有活跃的干性年龄相关性黄斑变性(AMD)眼睛组成,以确定观察期间和全黄斑区SDM后径向线性ARGA进展的速度。
49例ARGA患者的67只眼睛,平均年龄86岁,被确定在SDM治疗开始前后均有随访。所有患者均纳入研究。这些眼睛在SDM治疗前平均随访910天(2.5年),治疗后平均随访805天(2.2年)。对治疗与观察进行测量屏蔽后发现,ARGA病变半径在治疗前(对照组)每年进展1至540μm(平均137μm,标准差107);在开始定期全黄斑区SDM激光治疗后每年进展-44至303μm(平均73μm,标准差59)。因此,全黄斑区SDM后径向线性进展速度每年降低47%(p<0.0001)。没有不良治疗效果。
在高危干性AMD患者队列中,全黄斑区SDM使径向线性ARGA进展速度每年减慢47%(p<0.0001),且无不良治疗效果。若这些发现得到验证,将成为预防年龄相关性视力丧失的一项重要进展以及未来治疗的一个基准。